Laboratoire français de Fractionnement et de Biotechnologies
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, Laboratoire français de Fractionnement et de Biotechnologies sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Laboratoire français de Fractionnement et de Biotechnologies: 4 sponsored US clinical trials, none currently recruiting.
Laboratoire français de Fractionnement et de Biotechnologies sponsors 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 3 completed. 3 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hemophilia B With Inhibitors, with 1 trials.
Upper-quartile sponsor footprint
Laboratoire français de Fractionnement et de Biotechnologies sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
4 total, page 1 of 1
A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures SCOPE HIM
NCT05695391
Retrospective Experience Assessing the Real-World Utilization and Effectiveness of SEVENFACT®
NCT05904210
LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures
NCT02548143
A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa
NCT02448680
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 3 |
Therapeutic Areas
How the Laboratoire français de Fractionnement et de Biotechnologies archive is shaped
4 indexed studies, none listed as recruiting (0% open); 3 completed (75%).
Phase mix: 3 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Hemophilia B With Inhibitors (1 trial), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Laboratoire français de Fractionnement et de Biotechnologies: archived-pipeline peers nationwide
Peers matched on 4 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Laboratoire français de Fractionnement et de Biotechnologies sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 archived trials
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Laboratoire français de Fractionnement et de Biotechnologies page
4 registered trials is a research-attention snapshot, not an endorsement of Laboratoire français de Fractionnement et de Biotechnologies or any single study.
- None of Laboratoire français de Fractionnement et de Biotechnologies's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Hemophilia B With Inhibitors is the condition Laboratoire français de Fractionnement et de Biotechnologies studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hemophilia B With Inhibitors trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Laboratoire français de Fractionnement et de Biotechnologies pipeline card: 4 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.